What ExThera Medical does

ExThera Medical Corporation is a privately held, development-stage medical device company founded in 2007 and headquartered in Martinez, California. The company is developing extracorporeal blood filtration devices that use proprietary microbead adsorption media coated with chemically-bonded modified heparin to mimic the heparan sulfate receptors on human cells, enabling pathogens and circulating tumor cells to bind to the beads and be removed from a patient's bloodstream during hemoperfusion.

The company's product portfolio consists of two investigational devices. The Seraph 100 Microbind Affinity Blood Filter is a single-use extracorporeal hemoperfusion device designed to reduce pathogen levels in patients with severe bloodstream infections and sepsis; it was the first and only pathogen adsorption therapy to receive FDA Emergency Use Authorization for COVID-19 treatment in 2020 but has not received FDA market approval. The ONCObind Procedure Hemoperfusion Filter applies the same platform technology to remove circulating tumor cells from blood and received an FDA Investigational Device Exemption in July 2023 for studies in metastatic pancreatic ductal adenocarcinoma, with Phase I of the OSCAR I study completed in September 2024 reporting a 94% average reduction in circulating tumor cells after a single use.

ExThera has no commercial revenue and no commercially approved products in the United States. Its business model is contingent on future regulatory clearance, with planned go-to-market centered on direct sales to hospital ICUs, infectious disease departments, and oncology centers, supported by clinical trial partnerships with major institutions including Mayo Clinic and OU Health Stephenson Cancer Center. Capital formation has come primarily from venture funding led by Fresenius Medical Care Ventures ($15.3M Series B in August 2023), with additional Department of Defense sponsorship of sepsis trials. The company faces material regulatory headwinds, including a 2026 DOJ deferred prosecution agreement and FDA warning letter related to adverse event reporting and unauthorized promotional claims.

Name

ExThera Medical

Legal name

ExThera Medical Corporation

Website

https://extheramedical.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

ExThera Medical is a development-stage medical device company developing extracorporeal blood filtration devices (Seraph 100 and ONCObind) that use heparin-mimicking microbeads to remove pathogens and circulating tumor cells from bloodstream, targeting hospital ICUs and oncology centers pending FDA approval.

Ownership category

akta.pro rank

Product category

Therapeutic Apheresis and Blood Filtration Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)

akta.pro secondary industry

Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

Keywords

• Extracorporeal blood filtration
• Pathogen adsorption therapy
• Hemoperfusion devices
• Circulating tumor cell removal
• Blood purification technology

Headquarters

HQ city

Martinez

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Medical Device Sales: ExThera Medical is a development-stage company with no commercial revenue. Its Seraph 100 and ONCObind devices are investigational products not yet approved by FDA for commercial sale. The company is pursuing regulatory approval in the US and EU markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

ExThera Medical develops single-use extracorporeal hemoperfusion devices that use microbead adsorption media coated with chemically-bonded modified heparin to mimic human cell receptors. The Seraph 100 is designed to reduce pathogens (bacteria, viruses, fungi) in the bloodstream of patients with severe infections, while the ONCObind procedure applies the same platform to filter circulating tumor cells (CTCs) from blood in metastatic cancer patients. Both devices are currently investigational in the United States.

Product overview

ExThera Medical develops extracorporeal blood filtration devices for medical applications. The company's product portfolio consists of two main investigational devices: the Seraph 100 Microbind Affinity Blood Filter, a single-use extracorporeal device that uses heparin-mimicking microbeads to adsorb pathogens from the bloodstream and was previously authorized for emergency COVID-19 use in the US; and the ONCObind Procedure Hemoperfusion Filter, which applies similar adsorption technology to remove circulating tumor cells from the blood of cancer patients. Both devices are investigational in the United States and have not received FDA market clearance or approval.

Differentiator

Problem solved

Functional benefit

Brands

• ONCObind: ONCObind Procedure Hemoperfusion Filter for removing circulating tumor cells (CTCs) from blood of patients with metastatic cancer. FDA has granted Investigational Device Exemption (IDE) for study in patients with metastatic pancreatic ductal adenocarcinoma.
• Seraph 100

Products and services

• Seraph 100 Microbind Affinity Blood Filter A single-use extracorporeal hemoperfusion device that uses microbeads coated with molecular heparin receptor sites to adsorb and remove pathogens (bacteria, viruses, fungi) from the bloodstream of patients with severe infections, intended as an adjunctive treatment of bloodstream infections for use in hospitals, clinics, and austere environments. The device mimics heparan sulfate receptors on human cells that pathogens attack when invading the body.
• ONCObind Procedure Hemoperfusion Filter Extracorporeal blood filtration procedure designed to target and filter out circulating tumor cells (CTCs) from the bloodstream of cancer patients, based on ExThera's Seraph 100 platform technology. Studied for metastatic cancer treatment applications including pancreatic ductal adenocarcinoma under an FDA Investigational Device Exemption.

Quantifiable outcome

• 94% average reduction in circulating tumor cells after single use of Oncobind procedure
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Battelle Memorial InstitutecoreStrategic or Co-development PartnerCollaborative research partnership for DARPA's Dialysis-Like Therapeutics program to develop a dialysis-like therapeutic (DLT) intrinsic separation device to treat sepsis in wounded warriors. ExThera's technology was the only device evaluated in the final phase of the competitive program after other technologies were down-selected.
• Mayo CliniccoreStrategic or Co-development PartnerEnrolled first patient for ExThera Medical's PURIFY-RCT II trial to evaluate efficacy of pathogen removal from severely ill patients suffering from pathogen shock. The trial is sponsored by the Department of Defense in collaboration with the Henry M. Jackson Foundation and Uniformed Services University of Health Sciences.
• OU Health Stephenson Cancer CentercoreStrategic or Co-development PartnerClinical partner of the University of Oklahoma, enrolled first patient for ExThera Medical's OSCAR I STUDY to evaluate ONCObind procedure for removal of circulating tumor cells in patients with metastatic pancreatic ductal adenocarcinoma.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• CytoSorbents: Commercial-stage medical device company developing extracorporeal blood purification therapies (CytoSorb) for sepsis, cytokine storm, and other critical-care conditions. Direct competitor to ExThera's Seraph 100 in the hospital ICU blood-purification market.
• Spectral Medical: Clinical-stage company developing extracorporeal blood purification therapies for septic shock (PMX cartridge and the PMB hemoperfusion device). Competes with ExThera's pathogen-removal approach for severe bloodstream infections.

Emerging players

• Aethlon Medical: Early-stage company developing the Hemopurifier, an extracorporeal blood filtration device targeting viruses and tumor-derived exosomes. Adjacent technology and overlapping use cases in pathogen and cancer-related blood purification.
• Marker Therapeutics: Clinical-stage immuno-oncology company with circulating-tumor-cell-related programs. Adjacent in the oncology-circulating-tumor-cell treatment space where ExThera's ONCObind operates, representing an alternative modality for the same clinical problem.

Broad incumbents

• Jafron Biomedical: Leading manufacturer of hemoperfusion cartridges widely used in China and expanding globally. Direct overlap with ExThera's hemoperfusion-based pathogen removal technology and target customer base of ICU clinicians.
• Toray Medical: Division of Toray Industries that develops and markets hemoperfusion and other blood purification devices (e.g., Toraymyxin for endotoxin removal). Established global player in extracorporeal sepsis-treatment devices that overlaps with Seraph 100.
• Asahi Kasei Medical: Manufacturer of therapeutic apheresis and blood purification products used in critical care settings. Relevant incumbent in the broader extracorporeal blood-treatment category where ExThera operates.
• Baxter International: Diversified medical products company with established blood therapies, renal care, and continuous renal replacement therapy (CRRT) product lines serving hospital ICUs. Competes broadly with ExThera for ICU blood-treatment budgets and prescriber mindshare.
• Fresenius Medical Care: Global leader in dialysis and blood-related technologies, parent of ExThera's lead investor Fresenius Medical Care Ventures. Provides distribution scale and strategic context for evaluating ExThera's commercial pathway.

Regional players

• Nikkiso: Japanese manufacturer of medical devices including hemodialysis and blood purification systems. Regional incumbent with comparable extracorporeal blood-treatment technology primarily serving Asia-Pacific markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/extheramedical
• Facebookfacebook.com/ExTheraMedical
• LinkedInlinkedin.com/company/exthera-medical-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExThera Medical